are elusive and complex. Animal models have therefore been extensively used in diabetes research in order to minimize the difficulties that are encountered in carrying out diabetes studies in humans [4] . Inbred mouse models of diabetes that carry natural genetic mutations, have been developed and used as valuable resources in dissecting the complex interaction between genes and environment in diabetes [5] [6] [7] . The Nagoya-ShibataYasuda (NSY) mouse, an inbred strain established from outbred Jcl:ICR mice [8] , spontaneously develops impaired glucose tolerance with both insulin resistance and impaired insulin secretion together with liver steatosis, in an age-dependent manner [9, 10] . Since these characteristics of this mouse strain are similar to those observed in a common form of human type 2 diabetes, the NSY mouse has been regarded as a model for human type 2 diabetes. Previously, we identified several genetic quantitative trait loci (QTL) that affect glucose tolerance [11] , liver steatosis and body weight mice were measured in each strain of mouse at 5, 10, and 15 weeks of age. The effects of HSD and HFD on body weight gain were compared to that in RD-fed mice in each strain.
Glucose tolerance test, insulin secretion, and insulin tolerance test
Glucose tolerance was assessed by an intraperitoneal glucose tolerance test (ipGTT) (2 g glucose/kg body weight) in overnight-fasted mice, and blood glucose levels were measured at 0, 30, 60, 90 and 120 min. The area under the glucose concentration curve (gAUC) was calculated according to the trapezoidal rule. Plasma insulin levels were also measured at 0 and 30 min. Impaired glucose tolerance was defined as a blood glucose concentration at 120 min during ipGTT of higher than 11.1 mmol/L. Insulin tolerance tests (ITT) were performed by intra-peritoneal injection of human insulin (0.5 units/kg body wt; Novorin; Novo Nordisk) in overnight-fasted mice.
Tissue weights and insulin content
After anesthetization (phenobarbital 50 mg/kg, i.p.), body weight and anal-nasal length were measured. Body mass index (BMI) was calculated as body weight in grams divided by the square of anal-nasal length in centimeters. The liver, mesenteric fat pads and epididymal fat pads were weighed. Insulin was extracted from the pancreas by the acid ethanol method. Pancreatic insulin content and plasma insulin concentration were measured as previously described [9] .
Liver steatosis
Livers were dissected and fixed in 10% formalin neutral buffer solution, pH 7.4 (Wako Pure Chemical Industries, Osaka, Japan). Liver sections were stained with Sudan III. White color of the liver tissue was correlated with fatty deposits stained red by Sudan IlI as previously described [12, 15] . Sudan III-stained liver sections of HSD-fed NSY and control NSY mice at 16 weeks of age were examined with a picture analysis software program, WinROOF (http://mitani-visual. jp/); the proportion of the area stained with Sudan III was calculated in each sample.
Hepatic gene expression profiling and validation
Based on our findings that HSD severely impaired glucose intolerance compared to HFD in NSY mice, total RNA was extracted from the liver of male C3H [12] , indicating that diabetes and liver steatosis in this animal model are under polygenic control.
In the present study, to elucidate the molecular mechanisms underlying diet-induced acceleration of diabetes, we investigated the effect of excessive dietary sucrose on diabetes and its related phenotypes in NSY mice and compared it to those in control C3H mice, which were previously reported to be the most glucose-tolerant strain among inbred strains of mice [13] . Furthermore, we analyzed hepatic gene expression profiles, since the liver has been reported to be a major organ for insulin resistance that results from sucrose feeding [14] . NSY mice exhibited considerable worsening of glucose tolerance and liver steatosis with consumption of a diet high in sucrose. The similarities between humans and the NSY mouse will facilitate our understanding of the molecular mechanisms of liver steatosis and diabetes induced by excessive sucrose intake in humans.
Materials and Methods

Mice and protocol design
NSY/Osa (NSY) mice and C3H/HeNCrj (C3H) mice were maintained in the animal facilities of Osaka University Graduate School of Medicine with a 12-h light/dark cycle in an air-conditioned room (22-25°C). The Osaka University Graduate School Guidelines for the Care and Use of Laboratory Animals were followed. Male mice were used for all of the experiments. The mice were fed a laboratory diet, CRF-1 (Oriental Yeast, Tokyo, Japan), containing 22.3% protein, 6.2% fat, 3.0% fiber, 6.5% ash, and 47.8% complex carbohydrate, and allowed free access to water. Groups of NSY and C3H mice were maintained on a high-sucrose diet (HSD) or high-fat diet (HFD) for 12 weeks (4-16 weeks of age) from weaning, and compared with those on the regular diet (RD) of CRF-1. Mice on the HSD were given water supplemented with 30% w/v sucrose as well as CRF-1. The HFD was prepared by mixing powdered CRF-1 and lard to result in a 50% fat content. Phenotype and gene expression analyses were performed at 16 weeks of age. Groups of 5-10 mice were used in each study. RNA preparation and histological examination were performed in separate subsets of mice (n = 5 in each group) in order to avoid using mice that were fasted prior to euthanization.
Change in body weight
Body weights of RD-fed, HSD-fed, and HFD-fed To standardize the amount of mRNA in each sample, RT-PCR of hypoxanthine-guanine phosphoribosyl transferase (Hprt) mRNA was performed in parallel, with primers 5'-CTCGAAGTGTTGGATACAGG-3' (forward) and 5'-TGGCCTATAGGCTCATAGTG-3' (backward).
Statistical analysis
All results are expressed as mean ± SEM. Change in body weight, blood glucose levels during ipGTT, and insulin secretion among the three groups were analyzed by two-way repeated-measurement ANOVA with post hoc analysis with Scheffe's test. The basal insulin concentration and concentration after glucose stimulation were compared by Student's t-test. Differences among phenotypic characteristics and gene expression levels were analyzed by one-way ANOVA with post hoc analysis with Scheffe's test. A p value less than 0.05 was considered statistically significant. All statistical analyses were performed using StatView version 5.0 software (SAS Institute, Cary, NC, USA).
Results
HSD, rather than HFD, accelerated body weight gain in NSY mice, but had no effect in C3H mice
As shown in Fig. 1A , in C3H mice, HSD had no effect on body weight gain throughout the experiment, but HFD resulted in a significantly elevated body weight compared to RD and HSD at 10 and 15 weeks of age. In contrast, in NSY mice, HSD had a greater effect on body weight gain than HFD as shown in Fig.  1B . HSD resulted in a significantly elevated body weight (50.4 ± 0.4 g) compared to HFD (44.6 ± 1.1 g, p < 0.001) and RD (34.0 ± 0.5 g, p < 0.0001) at 15 weeks of age. These data demonstrate that the effect of HSD and HFD on body weight gain differs depending (n = 1) and NSY (n = 1) mice fed HSD for 12 weeks, using ISOGEN (Nippon Gene, Tokyo, Japan), and subjected to microarray screening using Murine Genome U74Av2 Arrays (MGU74Av2) (Affymetrix, Santa Clara, CA, USA) according to the protocols of Affymetrix. Briefly, total RNA was isolated from the liver and cleaned using an RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) after which mRNA was collected from total RNA using an Oligotex TM -dT30 [Super] mRNA Purification kit (TaKaRa, Tokyo, Japan) and reverse-transcribed into cDNA using a SuperScript Choice system (Invitrogen, Tokyo, Japan) and T7-(dT) 24 primer (Amersham Biosciences, Piscataway, NJ, USA). The cDNA was cleaned and converted to labeled cRNA using a BioArray High Yield RNA Transcript Labeling Kit (Affymetrix). Biotin-labeled cRNA was fragmented and hybridized to the Murine Genome U74Av2 Array (Affymetrix), displaying probes for over 12,000 murine genes. Fluorescent images were read using a Hewlett-Packard G2500A Gene Array Scanner. Signal analysis was performed using Microarray Suite ver. 5.0 (Affymetrix).
Based on the results from microarray analysis, we selected five genes (Pparg, Hsd3b5, Cyp7b1, Mt1, and Mt2) that are reported to be related to hepatic steatosis, and two genes (G0s2 and Kat2b) that were recently reported to function in lipid metabolism. In the RT-PCR study, gene expression levels were quantified using a FluorChem IS-8000 (Alpha Innotetech Corporation, San Leandro, CA, USA). To validate the different expression levels of peroxisome proliferator-activated receptor gamma 1 (Pparg1), peroxisome proliferator-activated receptor gamma 2 (Pparg2), G0/G1 switch gene 2 (G0s2), K (lysine) acetyltransferase 2B (Kat2b), metallothionein 1 (Mt1), metallothionein 2 (Mt2), hydroxy-delta-5-steroid dehydrogenase, 3 beta-and steroid delta-isomerase 5 (Hsd3b5), and cytochrome P450, family 7, subfamily b, polypeptide 1 (Cyp7b1), semi-quantitative RT-PCR (n = 5 in each group of mice) was performed with the following primers designed with Primer 3 software (http://frodo. wi.mit.edu/cgi-bin/primer3/primer3_www.cgi): Pparg1 forward primer, 5'-AGAAGCGGTGAACCA CTGAT-3', backward primer, 5'-GAATGCGAGTGG TCTTCCAT-3'; Pparg2 forward primer, 5'-CTC-CTGTTGACCCAGAGCAT-3', backward primer, 5'-CAACCATTGGGTCAGCTCTT-3'; G0s2 forward primer, 5'-ACTGCACCCTAGGCCCAG-3', backward primer, 5'-GTCTCAACTAGGCCGAGCAC-3';
, but there was no significant difference between HSD and HFD groups. The incidence of impaired glucose tolerance at 16 weeks of age reached 100% (10/10) in HSD-fed NSY mice. In C3H mice as shown in Fig. 2C , HSD and HFD resulted in a slight, albeit significant, increase in fasted insulin concentrations. In contrast, the insulin concentration at 30 min was significantly elevated in HFD-fed C3H mice (188 ± 10.3% of that in RD-fed mice, p < 0.0001), suggesting that excess insulin secretion kept blood glucose at a normal level during the ipGTT. As shown in Fig.  2D , in NSY mice, both HSD-fed and HFD-fed animals exhibited significantly elevated fasted insulin concentrations compared to RD-fed mice (169 ± 10.8%, 207 ± 15.9%, p < 0.05 and p < 0.01, respectively), indicating the existence of insulin resistance, particularly in HFDfed mice. In addition, insulin secretion in response to glucose was markedly impaired (24 ± 4.2% decrease vs. the basal level, p < 0.05) in HSD-fed mice and a similar trend was observed in the HFD-fed group. In HSD-fed NSY mice, the insulin concentration at 30 min during the ipGTT was similar to that in RD-fed mice despite the existence of insulin resistance, indicating that they had insufficient insulin secretion to overcome their insulin resistance. A similar pattern of impaired insulin secretion was observed in aged mice at 36 weeks of age as previously reported [9] . These data suggest that HSD worsened glucose tolerance more markedly than HFD in NSY mice. Thus, we focused on the effect of HSD on glucose intolerance in the NSY mouse.
on strain of mouse.
HSD accelerated glucose intolerance more than HFD in diabetes-susceptible NSY mice
As shown in Fig. 2A , in C3H mice, HFD resulted in significantly elevated fasted blood glucose levels (4.3 ± 0.3 mmol/L) compared to that in HSD-fed (3.2 ± 0.1 mmol/L, p < 0.01) and RD-fed animals (3.4 ± 0.1 mmol/L, p < 0.05). In addition, blood glucose levels were higher in HFD-fed mice at 30 min compared to the RD-fed group, and higher in HSD-fed animals at 60 and 90 min compared to RD. However, these observed changes were small, and there were no differences in blood glucose level between the three groups at 120 min during the ipGTT, despite accelerated body weight gain in the HFD group.
In NSY mice as shown in Fig. 2B , HFD resulted in increased fasted blood glucose levels (6.2 ± 0.3 mmol/L) compared to those in HSD-fed (4.8 ± 0.3 mmol/L, p < 0.01) and RD-fed mice (4.0 ± 0.2 mmol/L, p < 0.0001). However, blood glucose levels at 90 and 120 min were significantly elevated in the HSD group compared to both HFD and RD-fed animals. The blood glucose level at 120 min was significantly higher in HSD-fed mice (20.1 ± 1.6 mmol/L) compared to that in HFD-fed (13.3 ± 1.0 mmol/L, p < 0.01) and RD-fed mice (8.2 ± 0.6 mmol/L, p < 0.0001).
In NSY mice, the gAUC was significantly higher in HSD-fed (2.53 ± 0.09, p < 0.0001) and HFD-fed mice (2.35 ± 0.09, p < 0.0001) compared to mice fed RD cose intolerance with increased insulin resistance and insufficient insulin secretion to overcome insulin resistance despite increased pancreatic insulin content.
Effect of HSD on diabetes-related phenotypes
In HSD-fed NSY mice, the total caloric intake was 1.6-fold greater than that in RD-fed NSY mice, resulting in 50% of the consumed calories coming from sucrose (one month average measurements at 10-14 weeks of age). Similarly, HSD-fed C3H mice had a 1.4-fold increase in caloric intake resulting in 62% of their calories coming from sucrose.
BMI in HSD-fed NSY mice was significantly increased by HSD (Table 1) . HSD-fed NSY mice exhibited much greater tissue weights of liver (p <
Pancreatic insulin content in each group of mice under different diet conditions
As shown in Fig. 3A , in C3H mice, pancreatic insulin content was slightly, albeit significantly, higher in HSD-fed animals (p < 0.05) compared to the other groups, suggesting that the markedly increased insulin secretion in response to glucose that we observed in the HFD-fed group was not associated with pancreatic insulin content. In contrast, as shown in Fig. 3B , pancreatic insulin content was markedly increased in HSD-fed NSY mice compared to HFD-fed (247 ± 17% increase, p < 0.001) and RD-fed mice (254 ± 20%, p < 0.01), although insulin secretion was lower in the HSD-fed group compared to HFD-fed mice. These data suggest that HSD leads to the development of glu- HSD-fed NSY mice was significantly larger than that in RD-fed NSY mice (44.4 ± 1.2%; n = 5, vs. 28.3 ± 0.2%; n = 5, p < 0.0001). These findings indicate that HSD induced liver steatosis in NSY, but not C3H mice.
Comparison of hepatic gene expression between HSD-fed NSY and C3H mice using a DNA microarray system The development of insulin resistance and liver steatosis in NSY mice was observed under HSD conditions. Since the liver is one of the major target organs of insulin, we compared the hepatic gene expression profile of HSD-fed NSY and C3H mice, using a DNA microarray system. Out of 12,000 genes, 322 (2.68%) exhibited a large difference in expression level (≥ 2.0, ≤ 1/2) between the two HSD-fed groups of mice. The 100 genes (50 up-regulated and 50 down-regulated) that displayed the largest fold difference in expression between NSY and C3H mice fed HSD are listed 0.001), mesenteric fat pads (p < 0.001), and epididymal fat pads (p < 0.001) than RD-fed mice suggesting that in NSY mice, HSD markedly accelerated insulin resistance accompanied by intrinsic fat accumulation.
HSD accelerated development of insulin resistance and liver steatosis in NSY mice
Fig . 4A shows the results of the ITT. The glucoselowering effect of insulin was markedly impaired by HSD in NSY mice. Macroscopic examination showed marked fat accumulation in the livers of HSD-fed NSY mice, but no visible fat accumulation in the livers of HSD-fed C3H mice. We previously reported that a macroscopic grade of fatty liver correlated well with microscopic measurements of lipid accumulation stained with Sudan III in this model [12] . Fig. 4B and Fig. 4C show Sudan III staining in the livers of RD-fed and HSD-fed NSY mice, respectively. The proportion of the area stained with Sudan III in liver sections of and lipid storage, has two isoforms, peroxisome proliferator-activated receptor gamma 1 (Pparg1) and peroxisome proliferator-activated receptor gamma 2 (Pparg2), encoded by a single Pparg gene. We designed specific probes to examine expression of both the Pparg1 and Pparg2 isoforms. The expression level of Pparg1 was higher (2.32 ± 0.42 fold), albeit not significantly, in RD-fed NSY mice than in RD-fed C3H mice (Fig. 5A) . Under the HSD, NSY mice exhibited an increase in the expression level of Pparg1 (1.54 ± 0.34 times that under RD), whereas there was no increase in C3H mice, resulting in a significant difference (3.38 ± 0.71 fold, p < 0.001) between the two strains. The expression level of Pparg2, which is predominantly expressed in adipose tissue [27] , was the same in the two strains under RD (Fig. 5B) . HSD-fed NSY mice, however, exhibited a marked, significant increase in Pparg2 expression level (5.05 ± 0.73 times that in RD-fed mice, p < 0.0001), whereas C3H mice showed no increase, resulting in a marked significant difference (6.72 ± 0.96 fold, p < 0.0001) between the two strains under HSD.
G0s2, another adipose tissue-specific gene [23] in Table 2 . We identified several genes that were previously reported to be differentially expressed under similar dietary conditions. The H2-Aa, Tubb2a and Cyp4a14 genes, for example, were reported to be differentially expressed in a mouse congenic strain carrying an obesity susceptibility QTL under obesigenic diets [16] . Furthermore, Pparg, Cyp4a10, Gstm2, Cd36, and Mt1 genes were reported to be differentially expressed in a long-term high-fat diet-induced obesity mouse model [17] .
Microarray validation by semi-quantitative RT-PCR
Changes in gene expression shown by DNA microarray analysis were further investigated. Semiquantitative RT-PCR analysis was performed for selected genes in all four groups (RD-fed C3H, HSDfed C3H, RD-fed NSY, and HSD-fed NSY). We chose 8 transcripts from 7 of the top 100 genes. Pparg, Mt1, Mt2, Hsd3b5, Cyp7b1 genes are reported to be related to hepatic steatosis [17] [18] [19] [20] [21] [22] . G0s2 and Kat2b were recently reported to function in lipid metabolism [23] [24] [25] [26] .
Pparg, a key regulator of adipocyte differentiation 6B). Under the HSD, NSY mice exhibited a marked decrease in its expression level (0.41 ± 0.07 fold, p < 0.01) compared to the level under RD, whereas its expression level was similar in C3H mice, resulting in a marked, significant difference (0.24 ± 0.03 fold, p < 0.001) between the two strains. These data indicate that Kat2b gene expression was more sensitive to HSD in NSY mice than in C3H mice. Next, we investigated Mt1 and Mt2, which are known to be involved in oxidative stress. The expression level of Mt1 was significantly lower (0.02 ± 0.01 fold, p < 0.001) in RD-fed NSY mice than in RD-fed C3H mice (Fig. 7A) . Under HSD, NSY mice exhibited slightly increased expression of Mt1 compared to that that was previously reported as a direct target for PPARgamma [24] , was differentially expressed in HSD-fed NSY mice in the DNA microarray analysis (Table 2) . Under HSD, NSY mice exhibited a significant increase in its expression level (2.90 ± 0.34 fold, p < 0.01) compared to that in RD-fed NSY mice, whereas there was no significant increase in C3H mice, resulting in a marked, significant difference (3.30 ± 0.80 fold, p < 0.001) between the two strains (Fig. 6A) .
KAT2B acetylates lysine in histones, which is involved in epigenetic-directed transcriptional regulation and metabolism [28] . Expression of Kat2b was significantly lower (0.50 ± 0.06 fold, p < 0.001) in RD-fed NSY mice than in RD-fed C3H animals ( Hsd3b5 was significantly lower (0.60 ± 0.07 fold, p < 0.001) in NSY mice than in C3H mice under RD (Fig.  8A ). Under HSD, NSY mice exhibited a further reduction in Hsd3b5 expression level (0.18 ± 0.02 fold, p < 0.0001) compared to that under RD, whereas HSDfed C3H mice showed a less marked reduction (0.55 ± 0.04 fold, p < 0.001), resulting in a marked difference (0.20 ± 0.02 fold, p < 0.0001) between the two strains. Similar changes were observed for Cyp7b1 in response to HSD. Hepatic gene expression of Cyp7b1 in HSDfed NSY mice was only 0.16 ± 0.03 fold that in HSDfed C3H mice (p < 0.05) (Fig. 8B ).
under RD, whereas expression was slightly decreased in C3H mice, resulting in a marked difference between the two strains. The expression level of Mt2 exhibited a similar trend to that of Mt1 (Fig. 7B) . The reduction of hepatic expression of both Mt1 and Mt2 is therefore specific to the NSY mouse. Finally, we examined two down-regulated genes: Hsd3b5, which is involved in steroid hormone metabolism, and Cyp7b1, which plays a role in bile acid metabolism (Table 2) , since the changes that we observed in expression of these genes are comparable to results from other studies that have performed microarray analysis to study steatohepatitis or the insulin-resistant obese mouse [21, 22] . The expression level of Pparg2 is induced early during the differentiation of cultured adipocytes and is expressed at a high level specifically in adipose tissue [33, 34] . The observed increase in hepatic Pparg expression in diabetes-susceptible NSY mice under HSD is consistent with previous studies showing up-regulated Pparg expression in the liver of a high-fat diet-induced obesity mouse model [17] as well as in the liver of obese patients with hepatosteatosis [18] . In our previous study, using a cross between the NSY and C3H mouse, we reported a QTL for fatty liver (Fl1n) on chromosome 6 where Pparg is located, with a maximum logarithm of odds score of 10.0 [12] . In that study, we investigated Pparg as a candidate gene for Fl1n and showed allelic variation between NSY and C3H mice [12] . These findings confirm that Pparg is a likely candidate for Fl1n, and suggest that genetically controlled Pparg expression is exaggerated by sucrose overload. Hepatic expression of G0s2 was markedly increased under HSD in NSY, but not C3H mice. G0s2 is most highly expressed in adipose tissue, followed by muscle, heart, and liver [24] . Its expression is increased during adipogenesis or administration of a Pparg agonist. Moreover, the G0s2 gene has been shown to be a direct target for Pparg [24] . Overexpressed G0S2 in HeLa cells was reported to localize to lipid droplets and prevent their degradation mediated by adipose triglyceride lipase (ATGL), whereas knock down of endogenous G0s2 accelerates lipolysis in adipocytes [23] . In the present study, a significant increase in the expression levels of Pparg2 and G0s2 was only observed in HSDfed NSY mice. It is possible that expression of these adipocyte-specific genes in the liver may be a cause of HSD-induced liver steatosis.
Epigenetic mechanisms are considered to integrate environmental signals for cells to modulate the functional output of their genome [35] . Epigenetic gene regulation has two major forms; DNA methylation and histone modification. KAT2B is involved in histone modification by acetylating lysine of histones. In addition, KAT2B was also shown to acetylate non-histone proteins in both humans and mice [36] , and was suggested to have effects on glycolysis, gluconeogenesis, the tricarboxylic acid cycle, and fatty acid metabolism [25, 26] . Given the importance of lysine acetylation of histone proteins as well as non-histone proteins, it would be of further interest to investigate the functions of liver proteins that are under the regulation of Kat2b in the NSY mouse.
In a previous study in a long-term high-fat diet-in-
Discussion
Results from the present study demonstrated that HSD, rather than HFD, caused marked glucose intolerance and liver steatosis in diabetes-susceptible NSY mice, but not in diabetes-resistant C3H mice. Hepatic gene expression analysis revealed a distinct regulation of gene expression under HSD between the two strains of mice. Specifically, two adipocyte-specific genes, Pparg2, which differentiates adipocytes, and G0s2, which controls lipid storage, exhibited a marked increase in expression predominantly in the NSY mouse. In contrast, expression levels of Kat2b, Hsd3b5, and Cyp7b1 were initially similar or lower than those in RD-fed C3H mice, but were further decreased by HSD. Furthermore, Mt1 and Mt2 exhibited extremely low expression levels in NSY mice independent of diet. Although the expression pattern of these genes has been reported to be associated with liver steatosis, other than the Pparg-G0s2 cascade, interactions among these genes are still unknown. Elucidation of the molecular mechanism that mediates interaction between nutritional/environmental factors and genetic factors will further improve our understanding of diet-induced type 2 diabetes in humans.
Recently, we reported that excessive hepatic triglyceride accumulation leads to insulin resistance in the Fatty Liver Shionogi mouse [29] . It is likely that dietinduced liver steatosis leads to hepatic insulin resistance and accelerates the development of impaired glucose tolerance together with impaired insulin secretion in HSD-fed NSY mice. In one study, a high-fat diet induced obesity and clear-cut diabetes with significantly increased fasting blood glucose (>240 mg/dL) and insulin levels [30] in C57BL/6J mice. Similarly, in a separate study, 16 weeks of a high-sucrose diet induced obesity and hepatosteatosis with increased blood glucose and insulin levels in C57BL/6J mice [31] . In our study, the HFD also induced obesity, glucose intolerance, and impaired insulin secretion in response to glucose in NSY mice. Unexpectedly, however, HFD resulted in milder glucose intolerance than HSD. Although the reason for this is unclear, it may be due to an excess intake of fructose by the NSY mice in our study. According to a previous report, excess fructose (a component of sucrose) intake resulted in hepatic insulin resistance [32] .
In the present study, hepatic gene expression of Pparg1 and particularly Pparg2 was sensitive to the HSD in NSY mice. In mice, Pparg1 is expressed at low levels in many tissues including the liver [27] , whereas with worsening of this condition when down-regulated.
In conclusion, our present study in diabetes-susceptible NSY and diabetes-resistant C3H mice demonstrated that HSD accelerated impaired glucose tolerance and liver steatosis in NSY, but not C3H mice. Comparison of hepatic gene expression in NSY and C3H mice, with and without HSD, revealed several genes that were differentially expressed including Pparg1, Pparg2, G0s2, Kat2b, Mt1/2, Hsd3b5, and Cyp7b1. In NSY mice, liver steatosis was associated with a combination of altered expression pattern of these genes induced by HSD. It is unclear, however, whether HSD directly affects the hepatic gene expression profile leading to liver steatosis. Short-term feeding of HSD might be an alternative way to address this question. duced obesity mouse model, Mt1 was reported to be up-regulated in the liver [17] , which appears to be a normal response to lessen oxidative stress induced by excessive fat inflow to the liver. In separate studies, down regulation of Mt was shown to contribute to the development of steatohepatitis [19, 20] , whereas targeted disruption of Mt1 and Mt2 led to moderate obesity [37] . Furthermore, Mt1-and Mt2-null mice were reported to develop obesity when fed a high-fat diet [38] . Taking these findings together, reduced expression of hepatic Mts, which is particular to NSY, could contribute to the development of steatosis and obesity in this strain under HSD. Mt was shown to be implicated in energy consumption at the mitochondrial membrane by regulating oxygen respiration [39] , and this may be a mechanism that links lower hepatic expression of Mts with steatosis.
Down-regulation of hepatic expression of Hsd3b5 and Cyp7b1 was reported to be associated with fatty liver and insulin resistance [21, 22] . In our study, hepatic expression of Hsd3b5 and Cyp7b1 was reduced in the NSY mouse, and was further decreased by HSD. Previously, we demonstrated that treatment of NSY mice with a bile acid-binding resin, colestimide, which is clinically used as a cholesterol-lowering agent, suppressed the development of liver steatosis and resulted in increased expression of Cyp7a1 (bile acid metabolism) [40] . Thus, it appears that Cyp7a1/Cyp7b1 is associated with remission of liver steatosis when up-regulated, and conversely
